Posted by Michael Wonder on 18 Aug 2020
FDA initiatives to accelerate the development of COVID-19 therapeutics
18 August 2020 - More than 750,000 deaths have occurred worldwide as a result of the novel coronavirus as of August 2020. Clinicians have reported a range of physiological abnormalities in severely ill COVID-19 patients, including respiratory distress, severe immune reactions, and cardiac and vascular complications.
Research also suggests that death rates are alarmingly high for patients requiring ventilator support, demonstrating the need for therapeutic interventions that can prevent the escalation of disease severity.
The FDA has taken a number of steps to accelerate the development of COVID-19 therapeutics, from issuing guidance documents for product developers, to creating initiatives to facilitate regulatory review.
